Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

NCT01553149 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

75

Enrollment

NIH

Sponsor class

Conditions

Neurofibromatosis Type 1
Recurrent Childhood Pilocytic Astrocytoma
Recurrent Childhood Visual Pathway Glioma

Interventions

DRUG: Lenalidomide
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)